doi:http://formularyjournal.modernmedicine.com/node/125395An experimental diabetes drug, TAK-875, demonstrated its ability to improve blood-sugar control with a low risk of hypoglycemia, according to phase 2 study results published online February 27 in The Lancet.Formulary s...
Dr James Garner, General Manager for TGRD Asia said, "We are very pleased and excited that the TAK-875 study has entered Phase III trials in this region. The data published inThe Lancetis very encouraging and TAK-875 is a potential therapy for the treatment of type 2 diabetes in the fut...
2012 . TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial . Lancet 379 : 1403 – 1411 .Burant CF, Viswanathan P, Marcinak J, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase...
The LancetC.F. Burant, P. Viswanathan, J. Marcinak, C. Cao, M. Vakilynejad, B. Xie, E. Leifke, TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial, Lancet 379 (2012) 1403- 1411....